{Reference Type}: Multicenter Study
{Title}: Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study.
{Author}: Gonzalez-Martinez A;Sanz-García A;García-Azorín D;Rodríguez-Vico J;Jaimes A;Gómez García A;Casas-Limón J;Díaz de Terán J;Sastre-Real M;Membrilla J;Latorre G;Calle de Miguel C;Gil Luque S;Trevino-Peinado C;Quintas S;Heredia P;Echavarría-Íñiguez A;Guerrero-Peral Á;Sierra Á;González-García N;Porta-Etessam J;Gago-Veiga AB;
{Journal}: Pain Med
{Volume}: 25
{Issue}: 3
{Year}: 2024 Mar 1
{Factor}: 3.637
{DOI}: 10.1093/pm/pnad141
{Abstract}: <B>OBJECTIVE: </B>To evaluate clinical characteristics, effectiveness, and tolerability of preventive anti- calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) in the elderly. Anti-CGRP mAbs have demonstrated efficacy and safety in patients with migraine although there is limited information regarding the elderly.<BR><B>METHODS: </B>We performed a multicenter case-control study of cases (patients over 65 years old) and controls (sex-matched patients under 55 years old) with migraine receiving anti-CGRP mAbs.<BR><B>METHODS: </B>We included the demographic characteristics, effectiveness-reduction in the number of monthly headache days (MHD) and monthly migraine days (MMD), 30%, 50%, and 75% responder rates-and treatment emergent adverse events (TEAEs). The primary endpoint was the 50% response rate regarding MHD at weeks 20-24; exploratory 50% response predictors in the elderly were evaluated.<BR><B>RESULTS: </B>In total, 228 patients were included: 114 cases , 114 controls-. Among cases 84.2% (96/114) were women, 79.8% (91/114) CM; mean age of cases 70.1 years old (range: 66-86); mean age of controls was 42.9 years old(range: 38-49). Cases had a higher percentage of vascular risk factors (P < .05),older age of onset (P < .001) and more reported prior preventive treatments (P < .001). Regarding effectiveness in cases, 50% response rate was achieved by 57.5% (42/73) at 20-24 weeks, with lower reduction in the MHD at 8-12 weeks (5 [7.2], 8 [9.1]; P = .001) and a higher reduction in MMD at 20-24 weeks (10.7 [9.1], 9.2 [7.7]; P = .04) compared to the control group. The percentage of TEAEs was similar in the 2 groups. Diagnosis of episodic migraine (EM) (P = .03) and lower number of MHD at baseline (P = .001) were associated with a 50% response in the elderly in univariate analysis.<BR><B>CONCLUSIONS: </B>Our study provides real world evidence of effectiveness and safety of anti-CGRP mAbs for migraine in patients without upper age-limit and possible predictors of anti-CGRP response in the elderly.